A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma
Abstract Osteosarcoma (OS), the most prevalent primary bone malignancy in adolescents, is typically treated with cisplatin‐based chemotherapy. However, the development of cisplatin resistance often leads to relapse or metastasis, significantly impairing therapeutic efficacy. To tackle this issue, pa...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | Englisch |
| Veröffentlicht: |
Wiley
2025-07-01
|
| Schriftenreihe: | Advanced Science |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1002/advs.202500632 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!